Currently, ASCO-SNO-ASTRO Guidelines recommend that patients with HER2+ BC with asymptomatic BMs, who have progressed on previous trastuzumab, pertuzumab, and/or trastuzumab emtansine-based therapy, may be given the combination of tucatinib, trastuzumab, and capecitabine. Here, ERBB2 is linked to breast cancer.